Degenerative Myelopathy Therapy
North Carolina State University (Study D19CA-033)
Evaluate a novel treatment aimed at silencing a genetic mutation associated with degenerative myelopathy, an incurable, progressive disease of the spinal cord.
Inclusion Criteria: Client-owned dogs with clinical signs of degenerative myelopathy and confirmed homozygous-affected mutation of the SOD1 gene.
Enrollment Site: North Carolina State University
North Carolina State University (Study ID: D12CA-053)
Find out why some dogs have poor therapeutic response to standard-of-care drugs and find new ways to optimize their therapy.
Inclusion criteria: Dogs diagnosed with proteinuria as a result of kidney disease primarily affecting the glomerulus and that is unlikely to be due to a concurrent disease outside the kidney.
Enrollment sites: North Carolina State University, Iowa State University, Ohio State University and Colorado State University
Calcium Oxalate Urinary Stones
University of Minnesota (Study ID: D17CA-017)
Investigate genetic mutations associated with increased risk for calcium oxalate urinary stones, a painful and common health problem in dogs. Information will inform development of new diagnostics, therapies and preventive strategies to better manage this condition.
Inclusion criteria: Purebred miniature schnauzer, bichon frise, shih tzu, border collie or dachshund with a history of calcium oxalate urinary stones.
Enrollment site: DNA collection kits and instructions available to owners and veterinarians in the United States.
Genetic Impact on Heart Drug Therapy
The University of California, Davis (Study ID: D18FE-014)
Determine if genetic mutations are linked to how well or how poorly a cat with heart disease responds to clopidogrel, a blood thinner used to prevent life-threatening blood clot complications. Findings may help facilitate personalized medicine decisions and improve outcomes for these patients.
Inclusion criteria: Client-owned cats diagnosed with the heart condition, hypertrophic cardiomyopathy.
Enrollment sites: University of California, Davis
Anti-Clotting Drugs and Heart Disease
The University of Georgia (Study ID: D16FE-015)
Compare the efficacy of two drugs for preventing recurrent thromboembolism (blood clots) in cats that have experienced and recovered from a prior clot event due to heart disease.
Inclusion criteria: Client-owned cats that have been diagnosed with a thromboembolism due to cardiac disease.
Enrollment sites: Any veterinarian can enroll a cat, but examination by a board-certified veterinary cardiologist is required for inclusion in the study.
University of California, Davis (Study ID: D17FE-018)
Evaluate the benefit of a drug to maintain diabetic remission (not requiring insulin shots) in cats.
Inclusion criteria: Cats that in good body condition and diagnosed as diabetic with a recent onset of remission.
Enrollment sites: The Ohio State University Texas A&M University, University of California, Davis, The Royal Veterinary College, (United Kingdom), and University of Queensland (Australia)
The University of Georgia (Study ID: D17EQ-304)
Determine how long infected horses shed Salmonella in their feces and use this new information to improve infection prevention and control.
Inclusion criteria: Horses that are shedding Salmonella (clinically or sub-clinically affected).
Enrollment sites: Throughout the United States and Canada; sample collections kits and instructions provided.
For More Clinical Trials
Visit the searchable clinical trials database at the AVMA Health Studies Database for a comprehensive list of pet clinical trials in the United States and Canada, including Morris Animal Foundation-funded clinical trials.
Be The First to Know
Be the first to hear about breakthroughs that help pets and wildlife have healthier, longer lives.